Integral Diagnostics (ASX:IDX) First Half 2025 Results

Key Financial Results

• Revenue: AU$252.9m (up 9.3% from 1H 2024).
• Net loss: AU$396.0k (loss narrowed by 99% from 1H 2024).
• AU$0.002 loss per share (improved from AU$0.29 loss in 1H 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Integral Diagnostics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

The company's shares are down 20% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Integral Diagnostics you should be aware of, and 2 of them are a bit concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.